Esmya rejection hits Allergan's streamlining
A US FDA complete response letter has dealt Allergan’s hopes of finding a buyer for its women’s health unit a serious blow.
Almirall spots an opportunity
The Spanish group shows again that there is a future in dermatology, but its Allergan deal really depends on the fate of one asset.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.